Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: Efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïeve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. ESMO 2017 Congress; abstract LBA5.
Toename behandelopties voor subgroep met HER2-positief coloncarcinoom
sep 2023 | Maag-darm-leveroncologie